Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens

Bone Marrow Transplantation volume 38, pages 413–416 (2006)Cite this article

Abstract

Systematic data on the ability of pegfilgrastim to mobilize stem cells after chemotherapy are scarce. We evaluated the efficacy of a single 6 mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. Between July 2004 and October 2005, 17 aggressive non-Hodgkin's lymphoma and 11 poor-risk Hodgkin's lymphoma were treated with cycles containing cisplatin-aracytin. At the end of chemotherapy, the patients received 6 mg of pegfilgrastim. Duration of grade 4 neutropenia, adverse events, time to neutrophil recovery, peak and harvest of CD34+ cells were recorded. Twenty-seven out of 28 patients harvested a median of 17.3 × 106/CD34+ cells (range 2.5–28.9) after a median of 9 days (range 8–12 days), with a single apheresis procedure in 25 cases. All patients had grade 3–4 neutropenia, median duration 3 days. The only adverse event was mild bone pain. To date, 13 patients have been autografted with a median of 15.4 × 106 CD34+ pegfilgrastim-mobilized cells per kg (range 2.5–28.9) with rapid and sustained engraftment. Mobilization, harvesting and autografting of pegfilgrastim-mobilized PBC can be successfully achieved in pretreated patients with aggressive lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Curran MP, Goa KL . Pegfilgrastim. Drugs 2002; 62: 1207–1213.

    Article  CAS  Google Scholar 

  2. Biganzoli L, Untch M, Skacel T, Pico JL . Neulasta (Pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia. Sem Oncol 2004; 31 (Suppl 8): 27–34.

    Article  CAS  Google Scholar 

  3. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514–519.

    Article  CAS  Google Scholar 

  4. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R et al. International Study Group. Open-label, randomized study of pegfilgrastim versus daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia Lymphoma 2003; 44: 1503–1508.

    Article  CAS  Google Scholar 

  5. Philip T, Guglielmi C, Hagenbreek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  6. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33–36.

    Article  CAS  Google Scholar 

  7. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cell into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225–231.

    CAS  PubMed  Google Scholar 

  8. Bruns I, Steidl U, Scheid C, Kronenwett R, Fenk R, Graeft T et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180–185.

    Article  CAS  Google Scholar 

  9. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  Google Scholar 

  10. Shpall EJ . The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999; 23: S13–S19.

    Article  Google Scholar 

  11. Anderlini P, Champlin R . Use of filgrastim for stem cell mobilization in high-dose cancer chemotherapy. Drugs 2002; 62 (Suppl 1): 79–88.

    Article  CAS  Google Scholar 

  12. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. A randomized, double-blind, phase 3 study of fixed-dose, single administration pegfilgrastim versus filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35.

    Article  CAS  Google Scholar 

  13. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leukemia Lymphoma 2003; 44: 1691–1696.

    Article  CAS  Google Scholar 

  14. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734.

    Article  CAS  Google Scholar 

  15. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951.

    CAS  PubMed  Google Scholar 

  16. Kroshinsky F, Hoelig K, Platzbecker U, Schleyer E, Ordeman R, Haack A et al. Single-dose pegfilgrastim after chemotherapy is highly effective in enhancing the mobilization of autologous CD34+PBSC in patients with lymphoid malignancies and solid tumors. Blood 2004; 104: 798a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Ematologia, Niguarda Ca’ Granda Hospital, Milan, Italy

    A Nosari, R Cairoli, D Ciapanna, L Gargantini, L Intropido, C Baraté, G Nador, L Pezzetti & E Morra

  2. Onco-Hematology Department, Servizio Immuno-Trasfusionale, Niguarda Ca’ Granda Hospital, Milan, Italy

    B Scarpati & L Santoleri

Authors
  1. A Nosari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Cairoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Ciapanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Gargantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Intropido
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Baraté
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Scarpati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Santoleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Nador
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Pezzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Nosari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nosari, A., Cairoli, R., Ciapanna, D. et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 38, 413–416 (2006). https://doi.org/10.1038/sj.bmt.1705459

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705459

Keywords

This article is cited by

Search

Advanced search

Quick links